Study S001603

Triple Therapy for Type 1 Diabetes With Insulin, Semaglutide, and Dapagliflozin

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record Study Protocol (PDF)

Registration

Registration: NCT03899402
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2; PHASE3
Masking: DOUBLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 78
Start: 2019-05-01
Primary completion: 2026-01-31
Lead sponsor: State University of New York at Buffalo
Conditions: Type 1 Diabetes Mellitus
Interventions: DRUG:Insulin; DRUG:Semaglutide; DRUG:Dapagliflozin; DRUG:Placebo to Dapagliflozin
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: OTHER:1987

Registered primary outcomes

Change in HbA1c following dapagliflozin [6 months]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0002174	Insulin, Semaglutide and Dapagliflozin in Adults With Type 1 Diabetes: Design and Methods of Triple Therapy for Type 1 Diabetes (TTT1)-An International Phase 3 Clinical Trial. Timmons JG, Diabetes, obesity & metabolism	2026	Randomized trial	PMID 42473259 DOI	cites ClinicalTrials.gov:NCT03899402; registry reference DERIVED:42473259